Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook

Stock Track

Feb 13, 2025

Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.

According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.

Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1176032432"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176032432\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176032432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176032432","market":"us","top_or_hot":-1,"title":"Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook","media":"Stock Track","content":"<p>Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.</p>\n\n<p>According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.</p>\n\n<p>Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Galapagos NV (GLPG) Stock Soars 5.11% on Promising Pipeline and Earnings Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 04:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.</p>\n\n<p>According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.</p>\n\n<p>Furthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLPG","symbol_name":"Galapagos NV","start_time":0,"source_url":"","article_id":"1176032432","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176032432","pubTimestamp":1739392476,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Galapagos NV  stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.According to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leuke","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLPG":"Galapagos NV"},"translate_title":"股票追踪Galapagos NV(GLPG)股价因管道和盈利前景看好而飙升5.11%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLPG":1},"content_text":"Galapagos NV (GLPG) stock surged 5.11% on Wednesday during intraday trading, outperforming the broader market. The biopharmaceutical company's strong pipeline, particularly its cell therapy platform targeting cancer, and expectations of better earnings appear to be driving the stock's upward momentum.\nAccording to the news report, Galapagos NV is focused on developing innovative medicines in oncology and immunology, with promising CAR-T candidates like GLPG5101 and GLPG5201 targeting lymphoma and leukemia. The company's decentralized CAR-T manufacturing platform enables fast and personalized treatments, potentially addressing unmet medical needs.\nFurthermore, Galapagos NV reported positive financial results for the third quarter of 2024, with an operating profit of €66.0 million, up from €23.0 million in the previous year. The company also had €3.3 billion in cash and investments, positioning it well for future growth and expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}